Establishment and Pathophysiological Characterization of Type 2 Diabetic Mouse Model Produced by Streptozotocin and Nicotinamide(Highlighted paper selected by Editor-in-chief,Pharmacology)

Access this Article

Search this Article

Author(s)

    • Ogata Taeko [他] OGATA Taeko
    • Department of Molecular Pharmacology and Pharmacotherapeutics, Graduate School of Pharmaceutical Sciences, Chiba University
    • UENO Koichi
    • Department of Geriatric Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Chiba University
    • ONO Kageyoshi
    • Department of Molecular Pharmacology and Pharmacotherapeutics, Graduate School of Pharmaceutical Sciences, Chiba University
    • YANO Shingo
    • Department of Molecular Pharmacology and Pharmacotherapeutics, Graduate School of Pharmaceutical Sciences, Chiba University

Abstract

This study was performed in order to establish a mouse model that represents the non-obese type 2 diabetes reflecting a majority of diabetic patients among Asian races and to show its pathophysiological profiles. Streptozotocin (STZ) was administered to C57BL/6J mice with or without nicotinamide (120 or 240mg/kg, STZ/NA120 or STZ/NA240), twice with an interval of 2d, and plasma glucose concentration, body weight, water intake, insulin contents and insulin signal-related proteins were monitored. STZ-induced hyperglycemia (fasting and non-fasting), body weight loss and polyposia were significantly depressed by NA dose-dependently. In STZ/NA120 and STZ/NA240 mice, pancreatic insulin content was retained by 28 and 43% of normal control (10.5±0.93μU/ml), respectively, and histological damage of pancreatic beta cells was also less severe than that observed in STZ mice. When given the calorie-controlled high fat diet, the STZ/NA mice caused hyperlipidemia, and significantly increased insulin resistance. These observations suggest that the combined administration of STZ and NA causes partial depletion of pancreatic insulin and that the high fat constituents lead to insulin resistance in this model. The present mouse model, therefore, well exhibits the recent diabetic pathophysiological characteristics of a majority of Asian patients.

Journal

  • Biological & pharmaceutical bulletin

    Biological & pharmaceutical bulletin 29(6), 1167-1174, 2006-06-01

    The Pharmaceutical Society of Japan

References:  26

  • <no title>

    LIPSON L. G.

    Am. J. Med. 80, 10-21, 1986

    Cited by (1)

  • <no title>

    JABER L. A.

    Diabetes Care 27, 234-238, 2004

    Cited by (1)

  • <no title>

    GELDING S. V.

    Clin. Endocrinol. (Oxf.) 40, 55-62, 1994

    Cited by (1)

  • <no title>

    JUNOD A.

    J. Clin. Invest. 48, 2129-2139, 1969

    Cited by (1)

  • <no title>

    OKAMOTO H.

    Princess Takamatsu Symp. 13, 297-308, 1983

    Cited by (1)

  • <no title>

    YAMAMOTO H.

    Nature (London) 294, 284-286, 1981

    Cited by (1)

  • <no title>

    GIROIX M. H.

    Int. J. Mol. Med. 9, 381-384, 2002

    Cited by (1)

  • <no title>

    ANDERSON T.

    J. Clin. Invest. 54, 672-677, 1974

    Cited by (1)

  • <no title>

    SCHEIN P. S.

    Cancer Res. 27, 2324-2332, 1967

    Cited by (1)

  • <no title>

    HARRIS R. B.

    Exp. Biol. Med. (Maywood) 228, 24-32, 2003

    Cited by (1)

  • <no title>

    KULKARNI R. N.

    Diabetes 52, 1528-1534, 2003

    Cited by (1)

  • <no title>

    LEE K. U.

    Diabetologia 31, 285-290, 1988

    Cited by (1)

  • <no title>

    ITO M.

    Environ. Toxicol. Pharmacol. 9, 71-78, 2001

    Cited by (1)

  • <no title>

    BOLINDER J.

    Transplant. Proc. 20, 475-478, 1988

    Cited by (1)

  • <no title>

    SUN A. M.

    Diabetes 23, 424-432, 1974

    Cited by (1)

  • <no title>

    KENDALL D. M.

    N. Engl. J. Med. 322, 898-903, 1990

    Cited by (1)

  • <no title>

    HOTTA N.

    Diabetes Res. Clin. Pract. 19, 49-58, 1993

    Cited by (1)

  • <no title>

    HARA H.

    Diabet. Med. 13, S133-S142, 1996

    Cited by (1)

  • <no title>

    NAGASAKA S.

    Diabet. Med. 21, 136-141, 2004

    Cited by (1)

  • <no title>

    BONORA E

    Diabetes 53, 1782-1789, 2004

    DOI Cited by (2)

  • <no title>

    MASIELLO P.

    Diabetes 47, 224-229, 1998

    DOI Cited by (1)

  • <no title>

    BOIVIN A.

    Metabolism 44, 1540-1547, 1995

    DOI Cited by (1)

  • <no title>

    TOKUYAMA T.

    Metabolism 46, 1044-1051, 1997

    DOI Cited by (1)

  • <no title>

    PAIK S. G.

    Proc. Natl. Acad. Sci. U.S.A. 77, 6129-6133, 1980

    DOI Cited by (3)

  • <no title>

    SCHMID-Antomarchi H.

    J. Biol. Chem. 262, 15840-15844, 1987

    Cited by (10)

  • <no title>

    TOKUYAMA Y

    Metabolism 50, 812-818, 2001

    DOI Cited by (5)

Cited by:  3

Codes

  • NII Article ID (NAID)
    110005602261
  • NII NACSIS-CAT ID (NCID)
    AA10885497
  • Text Lang
    ENG
  • Article Type
    Journal Article
  • ISSN
    09186158
  • NDL Article ID
    7921442
  • NDL Source Classification
    ZS51(科学技術--薬学)
  • NDL Call No.
    Z53-V41
  • Data Source
    CJP  CJPref  NDL  NII-ELS  J-STAGE 
Page Top